Currently approved drugs for schizophrenia have proven useful; however, unmet medical needs still exist for this patient population. This program will shed light on possible mechanisms for an innovative class of therapeutics that have shown promise in schizophrenia by targeting muscarinic acetylcholine receptors in the brain.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
José Rey, MS, PharmD, BCPP
Professor of Pharmacy Practice Nova Southeastern University, Ft. Lauderdale, FL; Clinical Psychopharmacologist South Florida State Hospital, Wellpath Recovery Solutions, Pembroke Pines, FL
Learning Objectives
- Review the potential involvement of, and rationale for, targeting muscarinic receptors in schizophrenia.
- Introduce muscarinic agonists currently under investigation for the treatment of symptoms of schizophrenia.
Continuing Education Credit and Disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.